{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:36:05Z","timestamp":1793050565630,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"JSPS KAKENHI","award":["JP 21K16665"],"award-info":[{"award-number":["JP 21K16665"]}]},{"name":"Project Research Grant from Toho University School of Medicine","award":["No.19-19"],"award-info":[{"award-number":["No.19-19"]}],"id":[{"id":"https:\/\/ror.org\/02hcx7n63","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00198-026-08103-5","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T06:31:15Z","timestamp":1781591475000},"page":"2331-2342","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of romosozumab followed by denosumab in glucocorticoid users; a randomized clinical trial"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9822-8067","authenticated-orcid":false,"given":"Mai","family":"Kawazoe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Masuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2082-6948","authenticated-orcid":false,"given":"Kaichi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zento","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Koshiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9853-8057","authenticated-orcid":false,"given":"Sei","family":"Muraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izumi","family":"Irita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwa","family":"Kanaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7181-7494","authenticated-orcid":false,"given":"Takahiko","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3482-074X","authenticated-orcid":false,"given":"Toshihiro","family":"Nanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"8103_CR1","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s001980200108","volume":"13","author":"TP van Staa","year":"2002","unstructured":"van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777\u2013787","journal-title":"Osteoporos Int"},{"key":"8103_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s12020-018-1588-2","volume":"61","author":"J Compston","year":"2018","unstructured":"Compston J (2018) Glucocorticoid-induced osteoporosis: an update. Endocr 61:7\u201316","journal-title":"Endocr"},{"key":"8103_CR3","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1007\/s10067-017-3689-3","volume":"37","author":"M Kawazoe","year":"2018","unstructured":"Kawazoe M, Kaneko K, Shikano K, Kusunoki N, Nanki T, Kawai S (2018) Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases. Clin Rheumatol 37:2169\u20132178","journal-title":"Clin Rheumatol"},{"key":"8103_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00774-007-0821-5","volume":"26","author":"Y Kuroki","year":"2008","unstructured":"Kuroki Y, Kaji H, Kawano S et al (2008) Short-term effects of glucocorticoid therapy on biochemical markers of bone metabolism in Japanese patients: a prospective study. J Bone Miner Metab 26:271\u2013278","journal-title":"J Bone Miner Metab"},{"key":"8103_CR5","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s00198-015-3455-9","volume":"27","author":"MA Amiche","year":"2016","unstructured":"Amiche MA, Albaum JM, Tadrous M et al (2016) Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int 27:1709\u20131718","journal-title":"Osteoporos Int"},{"key":"8103_CR6","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","volume":"15","author":"TP Van Staa","year":"2000","unstructured":"Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993\u20131000","journal-title":"J Bone Miner Res"},{"key":"8103_CR7","doi-asserted-by":"crossref","unstructured":"LoCascio V, Bonucci E, Imbimbo B st al (1990) Bone loss in response to long-term glucocorticoid therapy. Bone Miner 8:39\u201351","DOI":"10.1016\/0169-6009(91)90139-Q"},{"key":"8103_CR8","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1007\/s00198-016-3646-z","volume":"27","author":"A Balasubramanian","year":"2016","unstructured":"Balasubramanian A, Wade SW, Adler RA et al (2016) Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis. Osteoporos Int 27:3239\u20133249","journal-title":"Osteoporos Int"},{"key":"8103_CR9","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00198-024-07023-6","volume":"35","author":"M Iki","year":"2024","unstructured":"Iki M, Fujimori K, Nakatoh S et al (2024) Average daily glucocorticoid dose, number of prescription days, and cumulative dose in the initial 90 days of glucocorticoid therapy are associated with subsequent hip and clinical vertebral fracture risk: a retrospective cohort study using a nationwide health insurance claims database in Japan. Osteoporos Int 35:805\u2013818","journal-title":"Osteoporos Int"},{"key":"8103_CR10","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","volume":"16","author":"P Chotiyarnwong","year":"2020","unstructured":"Chotiyarnwong P, McCloskey EV (2020) Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol 16:437\u2013447","journal-title":"Nat Rev Endocrinol"},{"key":"8103_CR11","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543","journal-title":"N Engl J Med"},{"key":"8103_CR12","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi M et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427","journal-title":"N Engl J Med"},{"key":"8103_CR13","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1093\/jbmr\/zjae116","volume":"39","author":"F Cosman","year":"2024","unstructured":"Cosman F, Oates M, Betah D et al (2024) Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension. J Bone Miner Res 39:1268\u20131277","journal-title":"J Bone Miner Res"},{"key":"8103_CR14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00774-014-0586-6","volume":"32","author":"Y Suzuki","year":"2014","unstructured":"Suzuki Y, Nawata H, Soen S et al (2014) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab 32:337\u2013350","journal-title":"J Bone Miner Metab"},{"key":"8103_CR15","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/art.40874","volume":"71","author":"KG Saag","year":"2019","unstructured":"Saag KG, Pannacciulli N, Geusens P et al (2019) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four-month randomized, double-blind, double-dummy trial. Arthritis Rheumatol 71:1174\u20131184","journal-title":"Arthritis Rheumatol"},{"key":"8103_CR16","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz023","author":"L Ding","year":"2020","unstructured":"Ding L, Hu J, Wang D et al (2020) Efficacy and safety of first- and second-line drugs to prevent glucocorticoid-induced fractures. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgz023","journal-title":"J Clin Endocrinol Metab"},{"key":"8103_CR17","doi-asserted-by":"publisher","first-page":"e2778","DOI":"10.1210\/clinem\/dgae810","volume":"110","author":"M Kawazoe","year":"2025","unstructured":"Kawazoe M, Kaneko K, Masuoka S et al (2025) Comparison of efficacy of romosozumab with denosumab and risedronate in patients newly initiating glucocorticoid therapy. J Clin Endocrinol Metab 110:e2778\u2013e2786","journal-title":"J Clin Endocrinol Metab"},{"key":"8103_CR18","volume-title":"2015 Guidelines for prevention and treatment of osteoporosis [in Japanese]","author":"Japan Osteoporosis Society","year":"2015","unstructured":"Japan Osteoporosis Society, Japanese Society for Bone and Mineral Research, Japan Osteoporosis Foundation (2015) 2015 Guidelines for prevention and treatment of osteoporosis [in Japanese]. Life Science Publishing Co., Tokyo"},{"key":"8103_CR19","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/mr\/roac014","volume":"33","author":"T Kobayakawa","year":"2023","unstructured":"Kobayakawa T, Miyazaki A, Kanayama Y et al (2023) Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administration. Mod Rheumatol 33:96\u2013103","journal-title":"Mod Rheumatol"},{"key":"8103_CR20","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/joim.20017","volume":"296","author":"CC Mok","year":"2024","unstructured":"Mok CC, Chan KL, Tse SM, Chen SPL, Tan KCB, Ma WH (2024) Romosozumab versus denosumab in long-term users of glucocorticoids: a pilot randomized controlled trial. J Intern Med 296:481\u2013494","journal-title":"J Intern Med"},{"key":"8103_CR21","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","volume":"18","author":"E Canalis","year":"2007","unstructured":"Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319\u20131328","journal-title":"Osteoporos Int"},{"key":"8103_CR22","doi-asserted-by":"publisher","first-page":"12002","DOI":"10.1016\/S0021-9258(18)37885-2","volume":"263","author":"MJ Weiss","year":"1988","unstructured":"Weiss MJ, Ray K, Henthorn PS, Lamb B, Kadesch T, Harris H (1988) Structure of the human liver\/bone\/kidney alkaline phosphatase gene. J Biol Chem 263:12002\u201312010","journal-title":"J Biol Chem"},{"key":"8103_CR23","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3899\/jrheum.100089","volume":"38","author":"SY Wang","year":"2011","unstructured":"Wang SY, Liu YY, Ye H et al (2011) Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis. J Rheumatol 38:821\u2013827","journal-title":"J Rheumatol"},{"key":"8103_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nrrheum.2014.188","volume":"11","author":"R Rizzoli","year":"2015","unstructured":"Rizzoli R, Biver E (2015) Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat Rev Rheumatol 11:98\u2013109","journal-title":"Nat Rev Rheumatol"},{"key":"8103_CR25","doi-asserted-by":"publisher","first-page":"E478","DOI":"10.1073\/pnas.1409857112","volume":"112","author":"X Tu","year":"2015","unstructured":"Tu X, Delgado-Calle J, Condon KW et al (2015) Osteocytes mediate the anabolic actions of canonical Wnt\/\u03b2-catenin signaling in bone. Proc Natl Acad Sci U S A 112:E478-486","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8103_CR26","unstructured":"Mean percentage change from baseline in serum sclerostin levels (subcutaneous cohort). 112292000_23100AMX00004_K109_1.pdf (pmda.go.jp) Accessed May 5 2026"},{"key":"8103_CR27","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1210\/jc.2013-1402","volume":"98","author":"AD Anastasilakis","year":"2013","unstructured":"Anastasilakis AD, Polyzos SA, Gkiomisi A, Bisbinas I, Gerou S, Makras P (2013) Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial. J Clin Endocrinol Metab 98:3206\u20133212","journal-title":"J Clin Endocrinol Metab"},{"key":"8103_CR28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00198-009-1066-z","volume":"21","author":"M Saito","year":"2010","unstructured":"Saito M, Marumo K (2010) Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 21:195\u2013214","journal-title":"Osteoporos Int"},{"key":"8103_CR29","volume-title":"Guide for the Use of Bone Metabolic Markers in the Diagnosis and Treatment of Osteoporosis (2018 edition)","author":"For the Committee on the Guidelines for the Use of Biochemical Markers of Bone Turnover in Osteoporosis JOSCO","year":"2018","unstructured":"For the Committee on the Guidelines for the Use of Biochemical Markers of Bone Turnover in Osteoporosis JOSCO (2018) Guide for the Use of Bone Metabolic Markers in the Diagnosis and Treatment of Osteoporosis (2018 edition). Life Science Publishing Co., Ltd., Tokyo"},{"key":"8103_CR30","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s00774-019-01017-9","volume":"37","author":"M Shiraki","year":"2019","unstructured":"Shiraki M, Kashiwabara S, Imai T, Tanaka S, Saito M (2019) The association of urinary pentosidine levels with the prevalence of osteoporotic fractures in postmenopausal women. J Bone Miner Metab 37:1067\u20131074","journal-title":"J Bone Miner Metab"},{"key":"8103_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/jog.16141","volume":"e16141","author":"K Matsuno","year":"2025","unstructured":"Matsuno K, Ueda K, Saito M et al (2025) Pilot study of the effect of surgical menopause on bone mineral density and quality in patients with gynecological malignancies. J Obstet Gynaecol Res 51","journal-title":"J Obstet Gynaecol Res"},{"key":"8103_CR32","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/joim.12873","volume":"285","author":"M Lorentzon","year":"2019","unstructured":"Lorentzon M (2019) Treating osteoporosis to prevent fractures: current concepts and future developments. J Intern Med 285:381\u2013394","journal-title":"J Intern Med"},{"key":"8103_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00774-003-0458-y","volume":"22","author":"Y Ogura","year":"2004","unstructured":"Ogura Y, Gonsho A, Cyong JC, Orimo H (2004) Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies. J Bone Miner Metab 22:111\u2013119","journal-title":"J Bone Miner Metab"},{"key":"8103_CR34","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00198-002-1369-9","volume":"14","author":"M Shiraki","year":"2003","unstructured":"Shiraki M, Fukunaga M, Kushida K et al (2003) A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group). Osteoporos Int 14:225\u2013234","journal-title":"Osteoporos Int"},{"key":"8103_CR35","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00774-006-0706-z","volume":"24","author":"H Kishimoto","year":"2006","unstructured":"Kishimoto H, Fukunaga M, Kushida K et al (2006) Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen. J Bone Miner Metab 24:405\u2013413","journal-title":"J Bone Miner Metab"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08103-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08103-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08103-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:01:22Z","timestamp":1793048482000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08103-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["8103"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-08103-5","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The present study was approved by the Ethics Committee of the Toho University Omori Medical Center (approval number; M18255, M23004), and adhered to the 1964 Declaration of Helsinki and its subsequent amendments as well as to the Ethical Guidelines for Medical and Health Research Involving Human Subjects by the Ministries of Education, Culture, Sports, Science and Technology and Health, Labour and Welfare of the Japanese Government. This study was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN000037239). All participants in this study provided their written informed consent.","order":1,"name":"Ethics","label":"Ethical statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MKawazoe received speaker fees from GlaxoSmithKline plc., Asahi Kasei Pharma Corp., AbbVie GK, Amgen K.K., Astellas Pharma Inc., AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corp., Nippon Boehringer Ingelheim Co., Ltd., Taiho Pharmaceutical Co., Ltd., and Taisho Pharmaceutical Co., Ltd. KKaneko received speaker fees from AbbVie GK, Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Ltd., GlaxoSmithKline K.K., Pfizer Japan Inc., and Takeda Pharmaceutical Co., Ltd. KF received a speaker fee from Asahi Kasei Pharma Corp. EW received grants from Bayer Yakuhin Co., Ltd. SY received speaker fees from Asahi Kasei Pharma Corp. and Taisho Pharmaceutical Co., Ltd. SMuraoka received a consulting fee from Asahi Kasei Pharma Corp., and speaker fees from GlaxoSmithKline plc., Ono Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mitsubishi-Tanabe Pharma Co., Asahi Kasei Pharma Corp., AbbVie GK, Astellas Pharma Inc., Taisho Pharmaceutical Co., Ltd., Eli Lilly Japan K.K. TS received speaker fees from AbbVie GK, Asahi Kasei Pharma Corp., Astellas Pharma Inc., Ayumi Pharmaceutical, Bristol Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Eisai Co., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Kissei Pharmaceutical Co., Ltd., Mitsubishi-Tanabe Pharma Co., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., and Taisho Pharmaceutical Co., Ltd. JN received grant\/research support from Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., AbbVie GK, Nippon Boehringer Ingelheim Co., Ltd., Nippon Kayaku Co., Ltd., Ayumi Pharmaceutical Corp., Abbott Japan LLC, and Taisho Pharmaceutical Co., Ltd., and speaker fees from Asahi Kasei Pharma Corp., Mitsubishi-Tanabe Pharma Co., and Taisho Pharmaceutical Co., Ltd. TN received grant\/research support from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Asahi Kasei Pharma Corp., Mitsubishi Tanabe Pharma Corp., Ayumi Pharmaceutical Corp., Nippon Kayaku Co., Ltd., AbbVie GK, Taisho Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., and Shionogi & Co., Ltd., consultant\/participation on a data safety monitoring board fees from UCB Japan Co., Ltd., Eisai Co., Ltd., and Chugai Pharmaceutical Co., Ltd., and speakers fees from Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Astellas Pharma Inc., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Asahi Kasei Pharma Corp., Eli Lilly Japan K.K., AbbVie GK, Ayumi Pharmaceutical Corp., Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corp., UCB Japan Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., AstraZeneca K.K., GlaxoSmithKline plc., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Kissei Pharmaceutical Co., Ltd., and Taisho Pharmaceutical Co., Ltd. The remaining authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","label":"Disclosure Statement","group":{"name":"EthicsHeading","label":"Declarations"}}]}}